The inhibition of neuronal apoptosis in acute traumatic and ischemic injuries as well as in long term neurodegenerative disorders like spinal muscular atrophy and possibly Alzheimer's disease is a fundamental requirement for a therapeutic strategy. In this study we used an established in vivo model system of induction of neuronal apoptosis in the CNS to evaluate the properties of the X-linked inhibitor of apoptosis protein (XIAP) to inhibit secondary cell death after axonal lesions. We used adenoviral vectors to transduce retinal ganglion cells after axotomy of the optic nerve of adult rats. Vector application was performed at the optic nerve stump so that only the lesioned retinal neurons could be transduced. We found XIAP to be as effective as the viral broad spectrum caspase inhibitor protein p35. These findings suggest that axotomized RGCs degenerate through class II caspase activity and furthermore offer the possibility of using mammalian XIAP protein to inhibit neuronal apoptosis as a basis for a regenerative therapy in the CNS. Cell Death and Differentiation (2000) 7, 815 ± 824.
Introduction
Although apoptosis is an important physiological process in the development of the central nervous system 1, 2 it has detrimental effects in the finally differentiated CNS, because degenerated neurons cannot be replaced in higher vertebrates. Apoptotic neuronal cell death has been claimed to contribute to neurodegenerative disorders such as spinal muscular atrophy, 3 and Alzheimer's disease 4 ± 6 and is also responsible for cell loss after ischemia and traumatic injury. 7 ± 10 It is of great clinical importance to reduce the neuronal cell loss as much as possible, allowing both for compensatory activity and as a basis for regenerative therapy.
The apoptotic program is executed by a family of specialized proteases termed caspases. 11, 12 The activation of inactive zymogens and the activity of the caspases can be inhibited by proteins expressed either by viruses or endogenously in mammalian cells. Viral anti-apoptotic proteins include p35 and IAP from baculovirus, 13, 14 CrmA from cowpoxvirus 15 and the v-Flip proteins from herpes viruses. 16 Several mammalian homologs of these viral proteins have been identified. The mammalian IAP homologs include XIAP, NAIP, cIAP 1 and 2 and survivin;
17 ± 20 a cellular Flip homolog with different isoforms has also been identified. 21 The various anti-apoptotic proteins exhibit different caspase-inhibitory properties. While CrmA and the Flips target the DISC-complex and inhibit caspase 8 activation, 15, 21 the IAPs directly inhibit the effector caspases 3 and 7, the BIR3-Ring domains of XIAP have also inhibitory properties for caspase 9. 17, 19, 22 p35 is a broad spectrum caspase inhibitor with similar K i for all caspases tested. 13 An established experimental paradigm for the induction as well as for studying the subsequent inhibition of neuronal apoptosis in the CNS, is the lesion of the retinotectal projection in the rat. Axotomy of the rat optic nerve leads to apoptotic cell death of the retinal ganglion cells (RGCs), which are the only retinal neurons projecting into the optic nerve. Fourteen days post lesion, over 80% of the retinal ganglion cells have degenerated. 23 ± 27 RGCs can be efficiently pre-labeled by retrogradely transported fluorescent dyes and thus cell survival can be quantitatively determined by counting labeled cells in the whole-mount retina. Also RGCs can be transduced by retrogradely transported viral vectors such as recombinant adenoviruses, 28, 29 when applied at the ocular side of the lesioned optic nerve stump.
It is the main advantage of this experimental system that only those neurons which are directly affected by the lesion can be transduced by the vectors. In this experimental paradigm p35 but not CrmA has been shown to promote RGC survival over a 14 day period post-lesion, indicating that cell death of axotomized ganglion cells is not death receptor dependent. 30 To further investigate the mechanisms leading to cell death in axotomized neurons and to evaluate the possibility of using autologous, cellular antiapoptotic proteins for protecting neurons from apoptosis in this paradigm, we used an adenoviral vector coding for XIAP, a specific class II (caspases 3 and 7 19 ) caspase inhibitor to transduce axotomized retinal ganglion cells.
We show that Ad.XIAP transduction is as efficient in inhibiting apoptosis in axotomized neurons as is Ad.p35 transduction, whereas two control vectors exerted no protective effect. These results indicate that viral p35 may be replaced in studies of inhibition of apoptosis or in therapies by the cellular XIAP with identical efficacy. These findings might be particularly important for long term studies in the CNS such as in the treatment of slowly progressing neurodegenerative disorders. Also, we add further evidence to recent findings 9, 27 that class II caspases are major executioners of apoptosis in lesioned CNS neurons.
Results

Vectors and vector application
We have used the Ad.Xiap vector along with several control vectors. Negative controls consisted of (i) vehicle alone (PBS/10% glycerol), (ii) a vector without a transgene in the E1 region (Ad.dE1) or (iii) a vector coding for EGFP in E1 (Ad.GFP). As a positive control, a vector coding for p35 (Ad.p35) was used, since it has already been shown to be neuroprotective in this experimental paradigm. 30 The Ad.Xiap vector was tested in vitro by transduction of cerebellar granule neurons after potassium withdrawal and showed inhibition of caspase 3 activity and enhancement of cell survival (Gerhard E, Ku È gler S, Leist M, Ba È hr M, Nicotera P, Schulz JB, manuscript in preparation). Furthermore, we investigated the neuroprotective properties of a vector coding for a secreted form of the neurotrophin CNTF (Ad.CNTF). The adenoviral vectors used in this study are schematically illustrated in Figure 1 . Viral particles were applied to the ocular side of the lesioned optic nerve stump in a 5 ml droplet; the viscosity of the solution (PBS/10% glycerol) kept the suspension in the open dura. The titre of all of the vectors was 2.5 ± 3610 8 p.f.u./ml. The viral suspension was not removed before closing the wound.
Monitoring of transgene expression in the retina
In order to demonstrate that RGCs are the only retinal cells transduced by the adenoviral vector application at the nerve stump and to allow for a semiquantitative determination of the rescue effects obtained after the various vector applications, we used an Ad.lacZ vector as reporter. In cryosections from transduced retinae, we found cells positive after staining with an anti-bGal antibody in the ganglion cell layer only (Figure 2A ), while no stained cells were detected in the other retinal layers or in retinae which were not transduced ( Figure 2B ). We also detected bgalactosidase expression in extraretinal tissue, as shown after histochemical X-Gal staining of retinal sections. Figure  2C shows transduced cells in the nerve stump, in the dura mater and in non-neural connective tissue. However, in retinae prepared for counting of surviving RGCs and for RNA extractions, these extraretinal tissues are virtually completely removed ( Figure 2D ). Part (a) of Figure 2D shows a whole mounted retina (histochemically stained with X-Gal for b-galactosidase activity) with labeled cells exclusively in the uppermost ganglion cell layer. Preparations of retinae for counting surviving RGCs and for RNA extraction were carried out in the same manner as for the bgalactosidase detection shown, thereby ensuring that no other transduced cells than RGCs were present in the preparations. Such specimen showed a distribution of labeled cells identical to that obtained after vector application to the superior colliculus ( Figure 2D part b) . This brain region is the target area for the axons of the RGCs. Obviously, only RGCs can be transduced by retrograde transport of the adenoviral vector after stereotaxic injections into the superior colliculus. Since the optic layer of the superior colliculus is a very thin but relatively large area which also shows topographically ordered projections of RGC axons, we found that in about 70% of the animals injected into the superior colliculus only part of Figure 1 Schematical representation of the adenoviral vectors used in this study. The transgenic E1 regions are shown in detail. MCMV=murine cytomegalovirus promoter; HCMV=human cytomegalovirus promoter; SV40pA=SV40 polyadenylation site; MYC=c-myc epitope; HA=HA epitope; NGF-L=nerve growth factor leader sequence; BHGE3, dl309=adenoviral backbones the retinae were transduced. Therefore, application of the vectors directly to the nerve stump is a favorable way of delivering transgenes specifically to RGCs in the retina.
After Ad.lacZ application, we detected b-galactosidase in about 10 ± 20% of all cells in the ganglion cell layer as determined by counting both b-galactosidase positive cells and DAPI stained nuclei. Since about 50% of all cells in the ganglion cell layer are displaced amacrine cells (which do not project to the optic nerve), we estimate that we transduced about 20 ± 40% of the total retinal ganglion cell population by this approach.
Since RGCs are the only retinal cells transduced by the vector application in our experimental setup, transgene expression could be readily monitored by RT ± PCR of RNA extracted from isolated retinae. We investigated transgene expression from the Ad.Xiap, Ad.CNTF and Ad.p35 vectors at 7 and 14 days after axotomy and transduction. RNA was reverse-transcribed with primers specific for the respective transgene mRNAs plus a primer for the internal standard, G3PDH. To exclude the possibility of amplification of endogenous Xiap or CNTF mRNA, the sense primers for the virally encoded transgenes were placed in the Nterminal fusions of these peptides (i.e. the Myc tag in the XIAP and the NGF leader sequence in the CNTF transgene).
For all three transgenes we used a nested PCR approach for highest specificity. Under the amplification conditions applied no products were detectable after the first amplification, whereas correctly-sized products were obtained after the second, nested PCR amplification ( Figure 3A ,C,D). Densitometric scanning of the obtained PCR products and comparison of expression levels at 7 and 14 days post axotomy/transduction, respectively, revealed a moderate decrease in all three transgene mRNA levels as compared to the G3PDH standard. Depending on the individual experiment, the relative expression levels after 14 days were 45 ± 80% as compared to the levels at 7 days (n=3 amplifications for each cDNA). No amplification products were obtained in the reverse transcriptase negative reactions, thus excluding the potential amplification of vector genomes.
The XIAP protein translated from the respective Ad vector was N-terminally tagged with a c-myc epitope. This epitope allows the detection of the fusion protein without using a XIAP specific antibody. In protein extracts from Ad.Xiap-transduced MRC-5 fibroblasts, the myc-tagged XIAP was readily detected by using the anti-myc antibody 9E10 ( Figure 3B ). No protein was detected from control transduced cells (data not shown). However, in extracts from Ad.Xiap transduced retinae, we were not able to detect the myc-tagged XIAP protein but only detected a protein migrating at the size of endogenous c-Myc. Although the size difference between myc-tagged XIAP and c-Myc as predicted from the amino acid sequence is only small (67 versus 66 kDa), both proteins were readily separated on PAA gels. As shown in Figure 3B , the myctagged XIAP from lysates of MRC-5 cells migrates somewhat above the band detected in untransduced retinae. In Ad.Xiap transduced retinae, no additional band is detected, indicating that the amount of XIAP produced by the transduced RGCs is not sufficient for detection by Western blotting, most likely because RGCs make up only a very small percentage (below 1%) of all retinal cells. Determination of the number of surviving RGCs after axotomy and transduction with viral vectors
To allow for quantification of surviving RGCs after ON axotomy and various treatments, RGCs were fluorescently prelabeled by injection of the retrogradely transported fluorescent dye, Di-I, into the superior colliculi (the target region of the RGCs in the midbrain) of neonatal rats. Axotomy and subsequent vector application were performed on these animals when they were 10 weeks old. Labeled RGCs were counted in whole-mounted retinae 14 days after the axotomy and the viral vector applications. The membrane bound Di-I fluorophor showed a characteristic punctate staining pattern in RGCs of unlesioned control retinae ( Figure 4A ). For quantification of surviving RGCs, only those cells were counted which had a normal morphology as compared to unlesioned RGCs and which have retained the uniformly distributed label (marked C=counted in Figure 4B ). Cells with obviously condensed membranes as judged from strong spotlike accumulation of label (marked N=not counted in Figure 4B ) were excluded from counting. Cells which showed only limited label accumulation were counted as surviving cells since focusing revealed a normal morphology and such partial label accumulation was also observed in RGCs from control retinae.
In the absence of a treatment or after vehicle application approximately 320 RGCs/mm 2 showed normal morphology and homogenous fluorescence which was well in accordance with previous studies using other fluorescent labels. Figure 5 shows the numbers of surviving RGCs counted 14 days post axotomy and viral transductions. The relative amount of RGCs surviving axotomy was determined as follows: in normal, untreated control retinae about 1900 RGCs/mm 2 were counted, which is well in agreement with previous studies. 23, 26, 27 Transduction with the Ad.lacZ reporter vector revealed that about 30+10% of the total population of RGCs is transduced by our vector application mode, which corresponds to 570+190 RGCs/mm 2 . Since after Ad.Xiap application 330 RGCs/mm 2 were still alive 14 days post axotomy due to the transduction with this vector, we estimate that roughly half of the transduced RGCs were rescued from apoptosis by this approach. Note that both histochemistry of whole mounted retinae (X-Gal staining) and immunological detection of b-galactosidase expression on frozen sections revealed pronounced differences in the signal intensities, suggesting differences in the uptake of the amount of vector by individual axons, which seems to result in quite different amounts of transgene production. 
Endogenous XIAP expression in the rat retina
As shown above, about 18% of the total RGC population survived axotomy without any treatment. It is unknown by which means these cells are protected from apoptosis. By staining cryosections from control retinae with an anti-XIAP antibody, we detected strong XIAP immunoreactivity in the ganglion cell layer and weaker immunoreactivity in the inner nuclear layer ( Figure 6B) . Specificity of the antibody was confirmed by omitting it from the labeling reaction and by mono-specificity on Western blots. Furthermore, RT ± PCR with subsequent restriction digest analysis of the PCR fragments obtained for two XIAP specific amplicons revealed expression of endogenous XIAP mRNA in the retina (data not shown).
The RGCs of the respective animals were prelabeled by fluorogold injection into the superior colliculi, allowing to precisely discriminate between RGCs and e.g. displaced amacrine cells in the retina. As judged from whole mounted preparations of such retinae, the labeling efficiency of RGCs is about 95% (not shown). A comparison between the staining patterns obtained by either the anti-XIAP antibody or the fluorogold label revealed that in the ganglion cell layer XIAP immunoreactivity is present nearly exclusively in RGCs ( Figure 6A ). We did not detect XIAP immunoreactivity in displaced amacrine cells in the ganglion cell layer, in cells with microglial nuclear phenotype, in the outer nuclear layer, in the photoreceptor layer nor in the main glial fraction of the retina, the Muller glia cells.
XIAP immunoreactivity was also detected in retinae from animal subjected to axotomy and Ad.XIAP application 14 days postlesion, with a clearly reduced number of immunoreactive RGCs as compared to unlesioned controls ( Figure 6C ).
Discussion
Apoptotic cell death contributes to neuronal degeneration in several paradigms including traumatic injury, ischemia/ stroke, spinal muscular atrophy and probably Alzheimer's disease. 3 ± 8,31 The prevention of neuronal degeneration is a fundamental basis for regenerative therapy and is also important in allowing compensatory remodeling of neuronal connections. We have recently shown that the baculovirus protein p35, which is a broad spectrum caspase inhibitor, efficiently prevents neuronal cell death in an in vivo model of axonal injury, the axotomy of the rat optic nerve. 30 In contrast, CrmA, which is a potent inhibitor of caspases 1 and 8, showed no neuroprotective effects in this experimental paradigm.
We have now attempted to substitute the viral p35 by an autologous mammalian protein, X-linked inhibitor of apoptosis (XIAP). XIAP, c-IAP-1 and c-IAP-2 have been shown to directly inhibit the downstream caspases 3 and 7 but not caspases 1, 6, 8 and 10.
10,17,19,32 XIAP was chosen for this study because it showed substantially higher caspase inhibitory activity than c-IAP-1 and -2. 19 Our results demonstrate that transduction with Ad.Xiap was as efficient in preventing ganglion cell death after axotomy as transduction with Ad.p35. Since XIAP is a specific type II caspase inhibitor, this finding adds further evidence to recent results demonstrating that caspase 3 is a major executioner of apoptosis in axotomized neurons. 27 However, recent findings suggest that IAPs may possess non caspase dependant anti apoptotic properties through their capability to interfere with the TNF receptor mediated NF-kB activation. 33, 34 In our group, we have investigated whether NF-kB is translocated to the nucleus following axotomy by both gel-shift assays and immunocytochemistry and have never observed such a translocation (R Diem and B Ba È hr, unpublished observations). Therefore, in agreement with previous experiments employing synthetic caspase inhibitors in the axotomy model, 27 we would suggest that the Xiap mediated anti-apoptotic mechanism in axotomized RGCs depends on class 2 caspase inhibition.
It has recently been reported that Xiap overexpression was neuroprotective in hippocampal CA1 neurons after transient ischemia. 9 In this case the vector was applied 7 days before the lesion (four vessel occlusion). In the present work, we applied the vector directly after lesioning which still resulted in highly significant neuroprotection. As the viral vector must be retrogradely transported after transduction, enter the nucleus and be unpacked before transcription of the transgene can begin, it appears to be sufficient to express the protective protein in the neuron some hours post-lesion. However, it remains to be determined whether there is a therapeutic window for the delivery of different anti-apoptotic proteins in the different experimental paradigms of neuronal apoptosis. At present, however, it appears that XIAP is an efficient autologous factor for the inhibition of neuronal apoptosis in the CNS. For long term expression of protective proteins which might be necessary for the inhibition of neuronal apoptosis in slowly progressing neurodegenerative disorders, the use of autologous proteins is preferable to viral proteins in order to avoid potential immunological problems.
We have also applied an adenoviral vector coding for the neurotrophic factor, CNTF, to the cut nerve stump. Although the mechanisms of neuroprotection and antiapoptotic properties afforded by CNTF are less well-defined than those of XIAP, we determined whether this secreted neurotrophic factor might be more effective in RGC rescue than the intracellular XIAP. In the construct employed, the CNTF had an amino terminal fusion to the NGF leader sequence, permitting the recombinant protein to be secreted from the transduced cells. This has indeed been shown recently for the vector used in this study. 29 The CNTF vector was efficient in rescuing RGCs after optic nerve axotomy and subsequent intraocular vector injection, which leads to transduction mainly of Mu È ller glia cells and some amacrine and bipolar cells in the retina. 35 After application on the nerve stump, however, Ad.CNTF administration did not rescue more ganglion cells than either the Ad.Xiap and Ad.p35 vectors, both of which code for intracellular proteins. This surprising result might either be due to the fact that CNTF acts only as a ligand for receptors on transduced cells or that not enough protein is secreted to be protective on larger cell numbers. It is interesting to note that in another paradigm of neuronal degeneration after axotomy (sciatic nerve lesion in newborn rats), intracellular anti-apoptotic proteins (NAIP, hIAP1 and hIAP2) were also as effective in cell rescue as the secreted neurotrophic factors BDNF and CNTF (Kato and Perrelet, personal communication).
As compared to our previous studies with the Ad.p35 and Ad.CrmA vector application, 30 the administration protocol of the vectors was slightly modified in this study. In our previous work we applied the vectors to the nerve stump for only 5 min, then removed the suspension and subsequently applied the tracer Fast Blue in order to label RGCs. Since the retinal ganglion cells in the present work have been prelabeled with the fluorescent tracer Di-I by injection into the superior colliculi, it was not necessary to remove the vector suspension from the nerve stump. We found no difference in the number of RGCs surviving axotomy with either application mode for the Ad.p35 vector. In contrast to previous results, however, we clearly detected expression from the viral vectors 14 days after transduction of RGCs. RT ± PCR analysis for the transgene expression was only semi-quantitative, since amplification of the internal reverse-transcription and amplification standard was carried out in reactions separately from the transgene's amplification, but we clearly detected a moderate decrease in the expression levels of all three transgenes. When comparing expression levels of XIAP, p35 and CNTF at 14 days after transduction to those at 7 days after transduction, we found a reduction to about 60%. Either, the viral promoters (MCMV) of the adenoviral vectors were attenuated as has been demonstrated for HCMV, RSV and LTR promoters in cell culture and organotypical slices 36, 37 or some transduced RGCs sequentially degenerate despite the presence of the antiapoptotic proteins. Since we have shown that the viral vectors are taken up in different quantity by individual axons, only those cells which were transduced by multiple copies of the vectors might survive for the 14 day period post-lesion. However, even if the apoptotic cell death is only postponed in the axotomized neurons, this delay in apoptosis execution might offer the possibility for additional interventions in order to prevent cell death ultimately.
It has recently been shown that caspase 3 is constitutively expressed in the adult rat retina. The activation of the zymogen occurred frequently in the outer nuclear layer and, after axotomy, in retinal ganglion cells. 38 Since a turnover of RGCs is impossible due to their long projection towards the superior colliculi, the expression of endogenous XIAP, as detected in unlesioned control retinae, may serve as a protective mechanism against sporadic activation of caspases. XIAP completely inhibits caspase 3 activity at equimolar ratios 22 and is cleaved into fragments with lower inhibitory properties only if caspase 3 is present in molar excess. Overexpression of XIAP from the respective adenoviral vector rescued a substantial number of axotomized RGCs from apoptosis. Therefore, it is tempting to speculate that the RGCs surviving axotomy without any neuroprotective treatment do so because they express amounts of XIAP high enough to inhibit caspase mediated apoptotic cell death without the need to overexpress this protein by gene transfer. At present, however, we cannot quantify the relative amounts of neuroprotection deriving from either endogenous or ectopically expressed XIAP. Further studies will have to prove whether endogenous XIAP expression at various levels is sufficient to inhibit apoptosis in axotomized RGCs.
In summary, the work presented here clearly demonstrates that the X-linked inhibitor of apoptosis (XIAP) is a useful factor for the inhibition of neuronal apoptosis after axonal lesion in the CNS. This is strengthened by recent results of others, who observed neuroprotection through XIAP overexpression in a model of transient ischemia. 9 Together with the finding, that NAIP, hIAP-1 and -2 proteins were protective after peripheral motoneuron axotomy (Kato and Perrelet, pers. communication), IAP family members represent a promising group of anti-apoptotic factors with the potential for neuroprotective therapy in neurodegenerative disorders.
As the primary trigger for apoptosis induction in axotomized RGCs remains unknown to date, the delivery of proteins which specifically interact in different apoptotic pathways may shed light on the mechanisms whereby neurons degenerate after an axonal lesion. In addition, the application of vectors coding for proteins of the Bcl-2 family and the Bax-inhibitor 39 will in the future help to define the participation of apoptosis induction via the mitochondrial pathway in these neurons in vivo.
Material and Methods
Prelabeling of retinal ganglion cells and animal surgery
To allow for accurate counting of RGCs, cells were retrogradely labeled with the fluorescent tracer 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (Di-I; Molecular Probes Inc., Oregon, USA). The skull cartilage of rat pups (postnatal day 7) was opened dorsal of the lambda fissure under diethylether anesthesia, and both superior colliculi were instilled with 5% Di-I in dimethylformamide using a micropipette. Optic nerve surgery was performed with prelabeled animals at the age of 10 weeks. Briefly, prelabeled animals were anesthetized by intraperitoneal injection of chloral hydrate (0.42 g/kg bodyweight). After skin incision close to the superior orbital rim, the orbita was opened taking care to leave the supraorbital vein intact. Following subtotal resection of the lacrimal gland, the superior extraocular muscles were spread by means of a small retractor. The ON was exposed by longitudinal incision of the eye retractor muscle and the perineurium. ON transection was performed in a distance of approximately 2 mm from the posterior pole of the eye without damaging retinal blood supply. Animals with persistent retinal ischemia (verified fundoscopically) were not included in the study. Viral vectors were applied to the ocular side of the nerve stump by placing a drop of about 5 ml into the opened dura. The viscosity of the solution used to store the virus (PBS/10% glycerol) retained the solution in the cavity of the opened dura. Immediately after vector application, the wound was closed. Application of vector into the optic layer of the superior colliculus was performed by stereotaxic injections: one injection was performed at bregma 75.8 mm, lateral 1 mm, dorsoventral 4.2 mm, a second injection was performed at bregma 76.5 mm, lateral 2.2 mm, dorsoventral 4.2 mm. 5610 8 p.f.u. of Ad.lacZ in 5 ml were injected in 5 min in each injection.
Quanti®cation of surviving RGCs
Fourteen days after ON transection, animals received an overdose of chloral hydrate, and the eyes were removed. The retinae were dissected, flat-mounted on gelatin-coated glass slides, and fixed for 20 min in 4% paraformaldehyde (PFA) in PBS. RGCs were examined under the fluorescence microscope (Axioplan 2, Zeiss, Jena, Germany). The number of Di-I positive RGCs was determined by counting them in 12 distinct areas of 62500 mm 2 each (three areas per retinal quadrant at three different eccentricities of 1/6, 1/2 and 5/6 of the retinal radius). Cell counts were performed according to a double blind protocol by two different investigators.
Statistics
Data are given as means+standard error of the mean (s.e.m.). Statistical significance was assessed using one-way ANOVA followed by Duncan test. Statistical analysis was performed using the absolute numbers of labeled RGCs. The number of cells surviving due to viral transduction was determined by subtracting the number of cells surviving without therapy from the values obtained with the different vector applications. Pairwise comparisons of groups was performed by a non-parametrical analysis of independent samples and MannWhitney-U-test.
Vector construction
Recombinant adenoviral vectors were constructed by homologous recombination in 293 cells according to standard procedures. 40 The pBHGE3 backbone plasmid and the pMH4 shuttle plasmid were used, except for the Ad.CNTF, which was constructed in d1309 as described elsewhere. 29 The pMH4 plasmid contains the short version (530 bp) of the murine cytomegalovirus (MCMV) promoter. Construction of the Ad.p35, Ad.dE1 and Ad.GFP has been described. 30 Ad.Xiap was constructed as follows: the coding sequence of the rat Xiap cDNA was excised from the pGEX-RIAP3 plasmid by BamHI-XhoI digestion. The Xiap fragment was cloned into the respective siters of the pCDNA6myc-HIAP1 plasmid, from which the HIAP1 fragment has been removed. This results in a coding sequence for rat Xiap with an Nterminal fusion of six copies of the myc epitope. By partial HindIII ± XhoI digestion the insert was isolated, blunt-ended and cloned into the blunt-ended BamHI site of the pMH4 shuttle plasmid. Protein production from the Ad.Xiap vector was verified by Western blotting after transduction of MRC-5 fibroblasts and detection of an appropriate product in protein lysates with the anti myc antibody 9E10 (Santa Cruz, Heidelberg, Germany).
Recombinant virus was grown in suspension culture, purified and concentrated by two rounds of CsCl 2 density gradient centrifugation and titers of transducing particles were determined by plaque assay. The amount of replication competent adenovirus (RCA) in the purified preparations was determined by a quantitative PCR approach, using primers as described. 29 If RCA was detectable it was found to be at least six orders of magnitude below the titres for recombinant vectors. All vector preparations contained negligible endotoxin levels below 0.005 IE/ml as determined by the quantitative cromogenic LAL assay (BioWhittaker, Walkersville, USA).
RNA preparation and RT ± PCR
Detection of transgene expression in transduced retinae was performed by RT ± PCR. Total RNA was extracted from control retinae and from retinae transduced for either 7 or 14 days with the respective recombinant virus, using the RNeasy kit (Qiagen, Hilden, Germany). Two to three eyes per group were used and the RNA was pooled prior to analysis. The RNA was spectrophotometrically quantified. One mg of RNA was digested with DNase and then was reverse transcribed with a Xiap specific primer (5'-gag atg tag act gtg tgg cac cgt-3') or p35 specific primer (5'-cgg caa tat taa act ctg cac aaa ctc ttc-3') or a CNTF specific primer (5'-gta aga gta tgt att gcc tga tgg aag-3') using Superscript reverse transcriptase (Life Technologies, Karlsruhe, Germany). Each reaction also contained a G3PDH specific reverse transcription primer, 5'-cca cgg cca tca cgc cac agc ttt c-3'. 10 pmoles of the Xiap, CNTF and p35 rt primers and 1 pmole of the G3PDH rt primer were used in the reverse transcriptions.
Nested PCRs were performed with the following primers: Xiap, 1st amplification: (5'-gaa atg gag agc ttg ggc ga-3') and (5'-ttg ggg ata ttc tcc tgt gtc ttc-3'), 2nd amplification: (5'-cat gga gca aaa gct cat ttc t-3') and (5'-tct atc tac tgc cgc gtg aca-3'); CNTF, 1st amplification: (5'-tgt tgt tct aca ctc tga tca ct-3') and (5'-tga aat gca ctc tct ggt c-3'), 2nd amplification (5'-tca cgt cgt ttt tga tcg-3') and (5'-ctt gga agg tac ggt aag c-3'), p35, 1st amplification: (5'-tca aat gga tgg att cca cg-3') and (5'-cca tca aac tgc aca ctg tc-3'), 2nd amplification: (5'-tga aca cta ttc ggt aag ttg c-3') and (5'-gac gtc gta ctc gta aag tcc-3'); G3PDH mRNA was amplified with primers 5'-cacggcaagttcaatg-3' and 5'-tctgagtgg-cagtgatg-3'. Cycling was performed with vent exo-polymerase (New England Biolabs, Schwalbach, Germany).
Histochemical detection of b-galactosidase activity and immunohistochemistry
Five days after axotomy and transduction with the Ad.lacZ vector, complete eyes were prepared. Specimens were fixed for 30 min in 1% PFA/solution 1 (100 mM K 2 HPO4, 5 mM EDTA, 2 mM MgCl 2 , 0.02% NP40) and then rinsed three times in excessive volumes of solution 1 and stained overnight at 378C in solution 2 (solution 1+10 mM K 3 Fe(CN) 6 FC, 10 mM K 4 Fe(CN) 6 FC, 750 mg/ml X-gal). After PBS wash, the eyes were embedded in TissueTek and frozen. Fourteen mm sections were prepared, postfixed in 4% PFA and counterstained with DAPI. For immunofluorescent detection, a polyclonal antibody specific for b-galactosidase was used (MoBiTek, Goettingen, Germany) at a dilution of 1 : 50 to stain 16 mm cryostat sections mounted to slides. Fluorescent detection was performed by using a Cy2 coupled antirabbit-IgG on a Zeiss Axiophot 2 microscope and recorded by a CCD Kamera (Zeiss, Goettingen, Germany). Expression of XIAP was detected by using a polyclonal anti-XIAP antibody (1 : 100). Fluorescence from the Cy3 coupled secondary antibody was recorded either as above or on a confocal laser scanning microscope (LSN 510, Zeiss, Goettingen, Germany).
